DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30

BRIGHT MINDS BIOSCIENCES INC.

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 23, 2025

$53.82+2.52 (+4.91%)

Close on Oct 19, 2026

BRIGHT MINDS BIOSCIENCES INC. balance sheet

Annual Quarterly

CAD USD

Millions of USD, except per-share data. Shares in millions.

Line item	Q4 2025 2025-09-30	Q4 2024 2024-09-30	Q4 2023 2023-09-30	Q4 2022 2022-09-30	Q4 2021 2021-09-30	Q4 2020 2020-09-30	Q4 2019 2019-09-30	Q4 2018 2018-09-30
Cash & Equivalents	60	4.23	4.99	8.46	16	0.60	0.06	0
Cash & Short-Term Investments	60	4.23	4.99	8.46	16	0.60	0.06	0
Total Current Assets	61	4.43	5.03	8.69	16	0.66	–	–
Operating Lease Right-of-Use Assets	0.08	0.09	0.05	0.10	0	–	–	–
Total Assets	61	4.52	5.08	8.79	16	0.66	–	–
Accounts Payable	1.62	0.33	0.15	1.02	0.50	0.11	–	–
Current Portion of Leases	0.06	0.06	0.05	0.05	0	–	–	–
Total Current Liabilities	1.68	0.39	0.21	1.07	0.50	–	–	–
Long-Term Leases	0.03	0.03	0	0.05	0	–	–	–
Operating Lease Liabilities	0.09	0.09	0.05	0.10	0	–	–	–
Total Liabilities	1.71	0.42	0.21	1.12	0.50	0.11	–	–
Common Stock	88	26	25	23	21	0.74	–	–
Retained Earnings	-33	-25	-23	-18	-7.27	-0.42	–	–
Total Equity	59	4.10	4.87	7.67	15	0.55	0.03	–
Total Liabilities & Equity	61	4.52	5.08	8.79	16	0.66	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 36.10
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 3550.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.